Mind Medicine Inc. (NASDAQ: MNMD) said in its earnings release that it has started dosing patients in two final-stage clinical trials for its LSD-based treatment aimed at generalized anxiety disorder.
The company, which develops treatments for mental health disorders, disclosed in its year-end financial results that it raised approximately $250 million…
Please login to read all 348 words.
